Cytosorbents Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTSO research report →
Price Chart
About the company
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood.
- CEO
- Phillip Chan
- IPO
- 2006
- Employees
- 129
- HQ
- Princeton, NJ, US
Get TickerSpark's AI analysis on CTSO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.11M
- P/E
- -0.90
- Fwd P/E
- 6.93
- PEG
- 0.01
- P/S
- 0.40
- P/B
- -6.54
- EV/EBITDA
- -3.37
- Div Yield
- 0.00%
- Gross Margin
- 72.91%
- Op Margin
- -28.63%
- Net Margin
- -45.05%
- ROE
- -1339.98%
- ROIC
- -39.34%
Latest fiscal year · YoY change
- Revenue
- $37.06M+4.1%
- Gross Profit
- $26.49M+6.4%
- Op Income
- $-14,239,000
- Net Income
- $-8,198,000+60.4%
- EPS
- $-2.60+65.8%
- OCF Growth
- +14.2%
- FCF Growth
- +14.8%
- 52W High
- $17.00
- 52W Low
- $2.84
- 50D MA
- $4.70
- 200D MA
- $8.85
- Beta
- 1.37
- RSI (14)
- 43
- Avg Volume
- 37.34K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cytosorbents said it reached operating cash flow breakeven in Q3, while improving gross margin and narrowing losses, and it is now leaning on Germany recovery, DrugSorb-ATR progress, and HemoDefend-BGA as future value drivers.· November 12, 2026
- Revenue was $9.7 million, up 3% year over year and 1% sequentially, with distributor/strategic partner sales up 18%.
- Product gross margin reached 75%, up 5 points year over year and 2 points from Q2, and management said it is targeting mid-70% margins consistently.
- The company said it achieved operating cash flow breakeven in Q3 excluding restructuring payments, with about $43,000 of positive operating cash flow.
- Adjusted EBITDA loss narrowed 86% to about $284,000, and operating loss improved to $1.2 million from $2.9 million a year ago.
- Management is planning a new BRILINTA DrugSorb-ATR De Novo submission in early 2027 and separately expects a DOAC submission in 2027.
Third-quarter revenue was $9.7 million, up 3% year over year and 1% sequentially. Product gross margin was 75%, up from 70% a year ago and 73% in Q2. Operating expenses were $8.5 million, down 11% year over year, and operating loss improved 59% to $1.2 million. Net loss was $1.8 million, or $0.58 per share, versus $3.2 million, or $1.01 per share, a year ago; adjusted net loss was $1.5 million, or $0.48 per share. Adjusted EBITDA loss narrowed 86% to about $284,000. The company said it generated about $43,000 of positive operating cash flow in the quarter excluding $251,000 of restructuring payments, ended with $5.7 million of cash equivalents and restricted cash, and had year-to-date cash used in operations of $2 million versus $7.6 million last year. For the first nine months, revenue was $28.2 million, gross margin improved to 73% from 71%, operating expenses fell 9% to $27.4 million, and adjusted EBITDA loss improved 45% to $4 million. Management did not give formal revenue or EPS guidance, but said it will work to remain at or near operating cash flow breakeven while selectively reinvesting in growth, and it expects to file the new BRILINTA De Novo in early 2027, with a separate DOAC submission in 2027.
Phillip Chan framed the quarter as a turning point because the company achieved its first operating cash flow breakeven milestone and now has a lower-cost operating model. His tone was constructive and confident, emphasizing that Cytosorbents now has four distinct value drivers: sustainable breakeven, renewed core business growth, DrugSorb-ATR, and HemoDefend-BGA. He highlighted that the company can selectively reinvest in Germany and other growth areas because gross margins are healthy and cash consumption has improved.
Peter Mariani focused on the mechanics behind the breakeven result: product gross margin improved to 75%, COGS fell 15% to $2.4 million, and operating expenses fell to $8.5 million, down 11% year over year and 12% sequentially. He said SG&A fell 18% to $7.1 million due to headcount reductions of about 24%, commercial restructuring, and tighter cost controls, while R&D was $1.1 million. He also pointed to positive operating cash flow of about $43,000 excluding restructuring payments, a quarter-end cash position of $5.7 million, inventory of $3.2 million, and a 73% reduction in year-to-date cash used in operations.
Analysts focused mainly on confidence in DrugSorb-ATR approval and whether the U.S. opportunity could produce revenue in 2027. Management said the key issue is demonstrating probable benefit outweighs probable risk, that FDA previously noted no major safety concerns, and that the new package should be stronger because it includes additional third-party analysis and a planned animal study. On timing, management reiterated an early-2027 submission target and said the statutory review period is 150 days, though Breakthrough Device and priority review status could accelerate that. They also said the FDA is still working through the nuances of the evidence package, but they are gaining clarity and aligning on a path forward.
The bull case from this call is that Cytosorbents now has evidence its cost reset is working, with gross margins in the mid-70s, losses narrowing sharply, and operating cash flow breakeven achieved. Management also pointed to improving distributor sales, renewed hiring in Germany, and multiple shots at value creation beyond the core business, especially DrugSorb-ATR and HemoDefend-BGA.
The main risks are that breakeven may not be linear, management explicitly said some quarters may still show modest cash burn, and the company ended with only $5.7 million of cash equivalents and restricted cash. Growth in Germany remains weak after a 20%-21% decline due to prior restructuring, and DrugSorb-ATR is still unapproved, with management depending on additional studies and FDA interactions before any 2027 submission, leaving regulatory timing and outcome uncertain.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 86.0%
- Shares Outstanding
- 3.15M
- Float Shares
- 2.71M
of shares held by institutions
51 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 2.20M | 0 |
| Avenir Corp | 259.09K | ▼ 4.93M |
| Cibc Private Wealth Group LLC | 172.65K | 0 |
| Northern Trust Corp | 111.66K | ▲ 19.12K |
| Neuberger Berman Group LLC | 10.42K | ▼ 1.96M |
| Tower Research Capital LLC (Trc) | 10.22K | ▲ 10.22K |
| Comerica Bank | 4.38K | ▲ 819 |
| Glenmede Trust Co NA | 1.08K | ▲ 1.08K |
Held by 24 ETFs
Biggest fund positions in CTSO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 15, 26 | Chan Phillip P. | buy | 3,774 |
| Sep 14, 26 | Capponi Vincent | buy | 273 |
| Sep 14, 26 | Capponi Vincent | buy | 1,800 |
| Sep 15, 26 | Sobel Alan D. | buy | 100 |
| Sep 15, 26 | Sobel Alan D. | buy | 500 |
| Sep 15, 26 | Sobel Alan D. | buy | 1,900 |
| Sep 4, 26 | Chan Phillip P. | buy | 200,000 |
| Jun 15, 26 | MARIANI PETER J | buy | 100,000 |
| Jun 15, 26 | Chan Phillip P. | buy | 10,333 |
| Jun 12, 26 | Chan Phillip P. | buy | 251,136 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CTSO coverage
Recent articles, reports, and earnings notes.
No research on CTSO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CTSO report →CytoSorbents Announces $6.25 Million Common Stock Financing Priced At-the-Market under Nasdaq Rules and Concurrent Restructuring of Avenue Capital Credit Facility
prnewswire.com · Nov 20
Cytosorbents Corporation (CTSO) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
CytoSorbents Reports Third Quarter 2026 Financial Results, Achieves Operating Cash Flow Breakeven, and Provides Business and Regulatory Update
prnewswire.com · Nov 12
CytoSorbents to Participate at the 2026 Jefferies Global Healthcare Conference in London
prnewswire.com · Nov 9
CytoSorbents to Report Third Quarter 2026 Financial Results and Recent Business Highlights
prnewswire.com · Oct 29
Cytosorbents (NASDAQ:CTSO) versus Electromed (NYSE:ELMD) Head to Head Comparison
defenseworld.net · Oct 11
Head to Head Survey: Zynex (NASDAQ:ZYXI) & Cytosorbents (NASDAQ:CTSO)
defenseworld.net · Oct 1
CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care
prnewswire.com · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.